Imaging agents are chemicals designed to allow clinicians to determine whether a mass is benign or malignant and locate metastatic cancer sites in the body.
The development of an imaging agent involves synthesizing the agent to target a particular tumor or process, after which the imaging instruments can be adjusted to neutralize the target. Such agents are first examined via preclinical animal studies before engaging in early-phase human clinical studies.